HDAC inhibitors in kidney development and disease.
The discovery that histone deacetylase inhibitors (HDACis) can attenuate acute kidney injury (AKI)-mediated damage and reduce fibrosis in kidney disease models has opened the possibility of utilizing HDACis as therapeutics for renal injury. Studies to date have made it abundantly clear that HDACi treatment results in a plethora of molecular changes, which are not always linked to histone acetylation, and that there is an essential need to understand the specific target(s) of any HDACi of interest. New lines of investigation are beginning to delve more deeply into target identification of specific HDACis and to address the relative toxicity of different HDACi classes. This review will focus on the utilization of HDACis during kidney organogenesis, injury, and disease, as well as on the development of these compounds as therapeutics.
Department of Developmental Biology, University of Pittsburgh, 3501 5th Ave., 5061 BST3, Pittsburgh, PA 15213, USA.
Lauren L
LL
Brilli
Lisa M
LM
Swanhart
Mark P
MP
de Caestecker
Neil A
NA
Hukriede
D000818:Animals; D056572:Histone Deacetylase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000196:embryology / Q000201:enzymology / Q000473:pathology; D007674:Kidney Diseases / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D038081:Organogenesis; D016896:Treatment Outcome
D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases